Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.26M | -11.39M | -14.08M | -18.34M | -43.70M |
| Total Depreciation and Amortization | 269.00K | 280.00K | 263.00K | 262.00K | 643.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | 3.11M | 4.34M |
| Total Other Non-Cash Items | 2.71M | 3.42M | 6.86M | 6.98M | 29.28M |
| Change in Net Operating Assets | 446.00K | 475.00K | -51.00K | -1.43M | -4.99M |
| Cash from Operations | -8.84M | -7.22M | -7.02M | -9.41M | -14.43M |
| Capital Expenditure | -42.00K | -39.00K | -37.00K | -22.00K | -19.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -42.00K | -39.00K | -37.00K | -22.00K | -19.00K |
| Total Debt Issued | 0.00 | 0.00 | 2.25M | 2.25M | 6.14M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.53M | 15.46M | 4.96M | 6.10M | 6.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | 0.00 |
| Other Financing Activities | -941.00K | -941.00K | -- | -135.00K | -135.00K |
| Cash from Financing | 9.59M | 14.51M | 7.21M | 8.22M | 12.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 713.00K | 7.26M | 155.00K | -1.22M | -2.37M |